Operational progress continues with ivonescimab (SMT112), an investigational, potentially first-in-class bispecific antibody combining the effects of immunotherapy via a blockade of PD-1 with the anti-angiogenesis effects associated with blocking VEGF into a single molecule.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SMMT:
- Summit Therapeutics options imply 7.3% move in share price post-earnings
- Summit Therapeutics put volume heavy and directionally bearish
- Summit partner selection for ASCO plenary signals strong OS, says Leerink
- Summit partner selection for ASCO ‘likely a major positive,’ says Guggenheim
- Biotech Alert: Searches spiking for these stocks today